

# JAK AND PI3K SIGNALING PATHWAY MARKETS



PHM168A  
April 2014

Shalini Shahani Dewan  
*Project Analyst*

ISBN: 1-56965-793-9

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	3
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ABOUT THE AUTHOR	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018) (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	11
JANUS KINASE (JAK) AND PHOSPHOINOSITIDE 3-KINASES (PI3K)	11
SIGNAL TRANSDUCTION THERAPIES/INHIBITORS FOR JAK AND PI3K	11
MECHANISM OF ACTION	12
Janus Kinase Therapies/Inhibitors	12
Phosphoinositide 3-kinases (PI3K) Therapies/Inhibitors	12
APPROVED HISTONE DEACETYLASE INHIBITORS	12
CLASSIFICATION	13
JANUS KINASE (JAK)	13
<i>TABLE 1 CLASSIFICATION OF JANUS KINASE (JAK)</i>	13
PHOSPHOINOSITIDE 3-KINASES (PI3K)	13
<i>TABLE 2 CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES (PI3K)</i>	14
JANUS KINASE THERAPIES/INHIBITORS	14
Ruxolitinib (INC424/INCB18424)	15
<i>FIGURE 1 STRUCTURE OF INC424 (RUXOLITINIB)</i>	15
Tofacitinib (CP-690,550)	15
<i>FIGURE 2 STRUCTURE OF CP-690,550 (TOFACITINIB)</i>	16
Baricitinib (INC28050/LY3009104)	16
<i>FIGURE 3 STRUCTURE OF BARICITINIB (INC28050/LY3009104)</i>	16
NS-018	17
Momelotinib (CYT-387)	17
<i>FIGURE 4 STRUCTURE OF MOMELOTINIB (CYT-387)</i>	17
AT9283	18
<i>FIGURE 5 STRUCTURE OF AT9283</i>	18
Pacritinib (SB1518)	18
<i>FIGURE 6 STRUCTURE OF PACRITINIB (SB1518)</i>	18
LY2784544	19
<i>FIGURE 7 STRUCTURE OF LY2784544</i>	19

<b>TOPIC</b>	<b>PAGE NO.</b>
TG101348 (SAR302503)	19
<i>FIGURE 8 STRUCTURE OF TG101348 (SAR302503)</i>	19
BMS911543	20
<i>FIGURE 9 STRUCTURE OF BMS911543</i>	20
Lestaurtinib (CEP-701)	20
<i>FIGURE 10 STRUCTURE OF LESTAURTINIB (CEP-701)</i>	20
LS104	21
WP1066	21
<i>FIGURE 11 STRUCTURE OF WP1066</i>	21
AG490	22
<i>FIGURE 12 STRUCTURE OF AG490</i>	22
AZD1480	22
<i>FIGURE 13 STRUCTURE OF AZD1480</i>	23
INCB39110	23
INCB47986	23
PHOSPHOINOSITIDE 3-KINASES (PI3K) THERAPIES/INHIBITORS	23
Wortmannin	24
<i>FIGURE 14 STRUCTURE OF WORTMANNIN</i>	24
Perifosine (KRX-0401)	25
<i>FIGURE 15 STRUCTURE OF PERIFOSINE (KRX-0401)</i>	25
LY294002	25
<i>FIGURE 16 STRUCTURE OF LY294002</i>	26
Idelalisib (GS-1101, CAL-101)	26
<i>FIGURE 17 STRUCTURE OF IDELALISIB (GS-1101, CAL-101)</i>	26
PX-866	27
<i>FIGURE 18 STRUCTURE OF PX-866</i>	27
IPI-145	27
<i>FIGURE 19 STRUCTURE OF IPI-145</i>	27
BKM120	28
<i>FIGURE 20 STRUCTURE OF BKM120</i>	28
Copanlisib (BAY80-6946)	29
<i>FIGURE 21 STRUCTURE OF COPANLISIB (BAY 80-6946)</i>	29
PF-05212384 (PKI-587)	29
<i>FIGURE 22 STRUCTURE OF PF-05212384 (PKI-587)</i>	30
Pictilisib (GDC-0941)	30
<i>FIGURE 23 STRUCTURE OF PICTILISIB (GDC-0941)</i>	30
Dactolisib (BEZ235)	31
<i>FIGURE 24 STRUCTURE OF DACTOLISIB (BEZ235)</i>	31
Apitolisib (GDC-0980)	31
<i>FIGURE 25 STRUCTURE OF APITOLISIB (GDC-0980)</i>	31
ZSTK474	32
<i>FIGURE 26 STRUCTURE OF ZSTK474</i>	32
SAR245409 (XL765)	32
<i>FIGURE 27 STRUCTURE OF SAR245409 (XL765)</i>	33
SAR245408 (XL147)	33
<i>FIGURE 28 STRUCTURE OF APITOLISIB SAR245408 (XL147)</i>	33
BYL719	34

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 29 STRUCTURE OF APITOLISIB BYL719</i>	34
SIGNAL TRANSDUCTION BIOMARKERS FOR JAK AND PI3K	34
PROSPECTIVE DISEASE TARGETS FOR JAK AND PI3K THERAPIES	35
<i>TABLE 3 SIGNAL TRANSDUCTION THERAPIES/INHIBITORS - PROSPECTIVE DISEASE TARGETS</i>	36
CHAPTER 4 REGULATORY ASPECTS	42
RUXOLITINIB (INC424)	43
DOSING INFORMATION	43
Dose Modifications	43
SAFETY INFORMATION	43
Safety of Ruxolitinib in Specific Population	44
RISK OF INFECTION	45
Tuberculosis	45
Progressive Multifocal Leukoencephalopathy (PML)	45
Herpes Zoster	45
TOFACITINIB (CP-690,550)	45
DOSING INFORMATION	45
Dose Modifications	45
SAFETY INFORMATION	46
Safety of Tofacitinib in Specific Populations	46
RISK OF INFECTION	47
Tuberculosis	47
REGULATORY DEVELOPMENTS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS	47
CHAPTER 5 NEW DEVELOPMENTS	50
NEW DEVELOPMENTS	50
<i>TABLE 4 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT</i>	51
<i>TABLE 5 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) IN COMBINATION WITH OTHER AGENTS</i>	57
<i>TABLE 6 NUMBER OF ONGOING TRIALS FOR MAJOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT AND COMBINATION THERAPY</i>	66
COLLABORATIVE TRIALS AND FUTURE ACTIVITIES	67
CHAPTER 6 MARKET ANALYSIS-SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)	70
MARKET BY THE TYPE	71
<i>TABLE 7 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	71
<i>FIGURE 30 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2011-2018</i>	71
RUXOLITINIB (INC424, INCB18424)-JANUS KINASE (JAK) INHIBITOR	72
Market Overview	72
Market Revenue	73
<i>TABLE 8 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	74
<i>FIGURE 31 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, 2011-2018 (\$ MILLIONS)</i>	74

<b>TOPIC</b>	<b>PAGE NO.</b>
TOFACITINIB (CP-690,550)-JANUS KINASE (JAK) INHIBITOR	74
Market Overview	75
Market Revenue	75
<i>TABLE 9 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	76
<i>FIGURE 32 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, 2011-2018 (\$ MILLIONS)</i>	76
MARKET SHARE	77
<i>TABLE 10 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)</i>	77
<i>FIGURE 33 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)</i>	77
MARKET BY REGION	77
MARKET OVERVIEW	78
MARKET REVENUE	79
<i>TABLE 11 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, THROUGH 2018 (\$ MILLIONS)</i>	79
<i>FIGURE 34 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2011-2018 (\$ MILLIONS)</i>	79
MARKET SHARE	80
<i>TABLE 12 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 (\$ MILLIONS)</i>	80
<i>FIGURE 35 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 (\$ MILLIONS)</i>	80
PROSPECTIVE FUTURE MARKET FOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)	81
INDUSTRY STRUCTURE	81
MARKET LEADERS	82
<i>TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS</i>	82
MARKET SHARES	83
<i>TABLE 14 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)</i>	83
<i>FIGURE 36 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)</i>	84
MARKET APPLICATIONS	84
<i>TABLE 15 APPLICATION AREAS OF COMBINATION THERAPY OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (FOR JAK AND PI3K) WITH OTHER THERAPIES</i>	85
MYELOFIBROSIS	86
RHEUMATOID ARTHRITIS	86
MARKET OVERVIEW	87
MARKET REVENUE	89
<i>TABLE 16 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	89
<i>FIGURE 37 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, 2011-2018 (\$ MILLIONS)</i>	89
MARKET SHARE	90

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 17 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%)</i>	90
<i>FIGURE 38 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%)</i>	90
PROSPECTIVE APPLICATION OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K)	91
CANCER	91
INFLAMMATORY DISEASES	92
CARDIAC AILMENTS	92
OTHERS	93
CHAPTER 7 PATENT ANALYSIS	95
PATENTS BY YEAR	96
<i>TABLE 18 TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013</i>	96
<i>FIGURE 39 TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013</i>	96
PATENTS BY SIGNAL TRANSDUCTION THERAPIES CATEGORY (JAK AND PI3K)	96
<i>TABLE 19 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS CATEGORY, 2011-2013</i>	97
<i>FIGURE 40 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS CATEGORY, 2011-2013</i>	97
PATENTS BY SIGNAL TRANSDUCTION THERAPIES TYPE	97
PATENTS BY JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS	97
<i>TABLE 20 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	98
<i>FIGURE 41 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	98
PATENTS BY PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS	98
<i>TABLE 21 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	99
<i>FIGURE 42 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	99
PATENTS BY COUNTRY	99
JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS	99
<i>TABLE 22 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	100
<i>FIGURE 43 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	100
<i>TABLE 23 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)</i>	101
<i>FIGURE 44 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)</i>	101
PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS	102
<i>TABLE 24 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	102
<i>FIGURE 45 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	102
<i>TABLE 25 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)</i>	103

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 46 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)</i>	103
PATENTS BY COMPANY	103
JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS	103
<i>TABLE 26 NUMBER OF U.S. PATENTS BY COMPANY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	104
PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS	105
<i>TABLE 27 NUMBER OF U.S. PATENTS BY COMPANY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	105
PATENTS BY ASSIGNEE	106
JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS	106
<i>TABLE 28 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	106
<i>FIGURE 47 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	106
PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS	107
<i>TABLE 29 PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	107
<i>FIGURE 48 PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013</i>	107
CHAPTER 8 CURRENT SITUATION	110
NEW TECHNOLOGIES AND PLATFORMS IN SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)	111
SCREENING TECHNOLOGY	111
PYRAMID	111
BIOMARKERS	111
FACTORS AFFECTING THE SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET	112
CURRENT DRIVERS OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET	112
COLLABORATIONS/ACQUISITIONS	113
<i>TABLE 30 FUNDINGS IN SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K)</i>	113
CHAPTER 9 COMPANY PROFILES	117
ABBVIE INC.	117
AETERNA ZENTARIS INC.	117
AMGEN INC	119
ASTELLAS PHARMA INC.	119
ASTEX PHARMACEUTICALS INC	120
ASTRAZENECA PLC	121
BAYER HEALTHCARE PHARMACEUTICALS	121
CELL THERAPEUTICS INC	122
CURIS INC.	124
DAIICHI SANKYO CO. LTD	124
ELI LILLY AND CO.	125
EXELIXIS INC.	126

<b>TOPIC</b>	<b>PAGE NO.</b>
GALAPAGOS NV	126
GENENTECH INC	128
GILEAD SCIENCES INC.	128
GLAXOSMITHKLINE	129
INCYTE CORP.	130
INFINITY PHARMACEUTICALS INC.	132
ITALFARMACO S.P.A.	133
JANSSEN BIOTECH INC.	134
MEI PHARMA INC.	134
MERCK & CO. INC.	135
MILLENNIUM	135
NATIONAL CANCER INSTITUTE	136
NIPPON ZENYAKU KOGYO CO., LTD.	137
NOVARTIS INTERNATIONAL AG	138
NS PHARMA, INC	139
ONCOTHYREON INC	139
PATHWAY THERAPEUTICS LTD	140
PFIZER	141
PIRAMAL ENTERPRISES LIMITED	142
PORTOLA PHARMACEUTICALS INC	142
RIGEL PHARMACEUTICALS INC.	143
SANOFI ONCOLOGY	144
TEVA PHARMACEUTICALS INDUSTRIES LTD	145
TG THERAPEUTICS INC.	146
VERASTEM INC.	146
VERTEX PHARMACEUTICALS INC	147
WILEX AG	148
XCOVERY HOLDING COMPANY, LLC	148
CHAPTER 10 APPENDIX I-ABBREVIATIONS	151



**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018 (\$ MILLIONS)	8
TABLE 1 CLASSIFICATION OF JANUS KINASE (JAK)	13
TABLE 2 CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES (PI3K)	14
TABLE 3 SIGNAL TRANSDUCTION THERAPIES/INHIBITORS - PROSPECTIVE DISEASE TARGETS	36
TABLE 4 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT	51
TABLE 5 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) IN COMBINATION WITH OTHER AGENTS	57
TABLE 6 NUMBER OF ONGOING TRIALS FOR MAJOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT AND COMBINATION THERAPY	66
TABLE 7 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, THROUGH 2018 (\$ MILLIONS)	71
TABLE 8 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, THROUGH 2018 (\$ MILLIONS)	74
TABLE 9 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, THROUGH 2018 (\$ MILLIONS)	76
TABLE 10 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)	77
TABLE 11 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, THROUGH 2018 (\$ MILLIONS)	79
TABLE 12 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 (\$ MILLIONS)	80
TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS	82
TABLE 14 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)	83
TABLE 15 APPLICATION AREAS OF COMBINATION THERAPY OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (FOR JAK AND PI3K) WITH OTHER THERAPIES	85
TABLE 16 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, THROUGH 2018 (\$ MILLIONS)	89
TABLE 17 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%)	90
TABLE 18 TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013	96
TABLE 19 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS CATEGORY, 2011-2013	97
TABLE 20 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013	98
TABLE 21 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013	99
TABLE 22 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013	100
TABLE 23 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)	101
TABLE 24 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013	102
TABLE 25 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)	103

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 26 NUMBER OF U.S. PATENTS BY COMPANY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/Biomarkers, 2011-2013	104
TABLE 27 NUMBER OF U.S. PATENTS BY COMPANY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/Biomarkers, 2011-2013	105
TABLE 28 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/Biomarkers, 2011-2013	106
TABLE 29 PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/Biomarkers, 2011-2013	107
TABLE 30 FUNDINGS IN SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/Biomarkers (JAK AND PI3K)	113

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018) (\$ MILLIONS)	8
FIGURE 1 STRUCTURE OF INC424 (RUXOLITINIB)	15
FIGURE 2 STRUCTURE OF CP-690,550 (TOFACITINIB)	16
FIGURE 3 STRUCTURE OF BARICITINIB (INC28050/LY3009104)	16
FIGURE 4 STRUCTURE OF MOMELOTINIB (CYT-387)	17
FIGURE 5 STRUCTURE OF AT9283	18
FIGURE 6 STRUCTURE OF PACRITINIB (SB1518)	18
FIGURE 7 STRUCTURE OF LY2784544	19
FIGURE 8 STRUCTURE OF TG101348 (SAR302503)	19
FIGURE 9 STRUCTURE OF BMS911543	20
FIGURE 10 STRUCTURE OF LESTAURTINIB (CEP-701)	20
FIGURE 11 STRUCTURE OF WP1066	21
FIGURE 12 STRUCTURE OF AG490	22
FIGURE 13 STRUCTURE OF AZD1480	23
FIGURE 14 STRUCTURE OF WORTMANNIN	24
FIGURE 15 STRUCTURE OF PERIFOSINE (KRX-0401)	25
FIGURE 16 STRUCTURE OF LY294002	26
FIGURE 17 STRUCTURE OF IDELALISIB (GS-1101, CAL-101)	26
FIGURE 18 STRUCTURE OF PX-866	27
FIGURE 19 STRUCTURE OF IPI-145	27
FIGURE 20 STRUCTURE OF BKM120	28
FIGURE 21 STRUCTURE OF COPANLISIB (BAY 80-6946)	29
FIGURE 22 STRUCTURE OF PF-05212384 (PKI-587)	30
FIGURE 23 STRUCTURE OF PICTILISIB (GDC-0941)	30
FIGURE 24 STRUCTURE OF DACTOLISIB (BEZ235)	31
FIGURE 25 STRUCTURE OF APITOLISIB (GDC-0980)	31
FIGURE 26 STRUCTURE OF ZSTK474	32
FIGURE 27 STRUCTURE OF SAR245409 (XL765)	33
FIGURE 28 STRUCTURE OF APITOLISIB SAR245408 (XL147)	33
FIGURE 29 STRUCTURE OF APITOLISIB BYL719	34
FIGURE 30 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2011-2018	71
FIGURE 31 GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, 2011-2018 (\$ MILLIONS)	74
FIGURE 32 GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, 2011-2018 (\$ MILLIONS)	76
FIGURE 33 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)	77
FIGURE 34 REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2011-2018 (\$ MILLIONS)	79
FIGURE 35 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 (\$ MILLIONS)	80
FIGURE 36 MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)	84
FIGURE 37 GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, 2011-2018 (\$ MILLIONS)	89

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 38 MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/Biomarkers (JAK AND PI3K) BY APPLICATION, 2013 (%)	90
FIGURE 39 TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013	96
FIGURE 40 NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/Biomarkers CATEGORY, 2011-2013	97
FIGURE 41 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/ INHIBITORS/Biomarkers, 2011-2013	98
FIGURE 42 PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/Biomarkers, 2011-2013	99
FIGURE 43 NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/Biomarkers, 2011-2013	100
FIGURE 44 PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/Biomarkers, 2011-2013 (%)	101
FIGURE 45 NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/Biomarkers, 2011-2013	102
FIGURE 46 PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/Biomarkers, 2011-2013 (%)	103
FIGURE 47 PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/Biomarkers, 2011-2013	106
FIGURE 48 PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/Biomarkers, 2011-2013	107